You can buy or sell SURF and other stocks, options, ETFs, and crypto commission-free!
Surface Oncology, Inc. Common Stock, also called Surface Oncology, is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. Read More The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Surface Oncology, Inc. (SURF) Reports Q1 Loss, Tops Revenue Estimates
Surface Oncology, Inc. (SURF) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 65.91%. A quarter ago, it was expected that this company would post a loss of $0.69 per share when it actually produced a loss of $0.17, delivering a surprise of 75.36%. Over the last four quarters, the compa...
-$0.15 per share